Sato 2015.
Methods | 24‐week, prospective, randomised, open‐labelled, controlled trial |
Participants | Participants with type 2 diabetes who were suboptimally controlled despite receiving at least twice‐daily injections of insulin were enrolled in the trial |
Interventions | The participants were randomised to continuation of insulin treatment (insulin group) or addition of sitagliptin 50 mg‐100 mg daily to insulin treatment |
Outcomes | HbA1c, body weight, hypoglycaemia, treatment satisfaction |
Notes | ‐ |